Abstract 92P
Background
Nutrition and immune status are two important factors that affect the occurrence and prognosis of tumors. Evaluating the nutritional and immune status of patients before treatment plays an important role in guiding the development of treatment plans and predicting treatment tolerance. In view of this, this study investigated the nutritional and immune status (BMI, PNI, and lymphocyte subset (NKTB) typing and absolute count) of nasopharyngeal carcinoma patients before treatment, and compared them with the nutritional and immune status of healthy individuals undergoing physical examinations, hoping to provide reference for the assessment of nutritional and immune status of nasopharyngeal carcinoma patients before treatment.
Methods
The study investigated the pretreatment nutritional and immune status (BMI, PNI, and percentage and absolute count of lymphocyte subpopulation) of 201 Newly diagnosed NPC cases and 332 age-sex-matched healthy controls.
Results
PNI was lower in patients with NPC than in healthy controls in both sexes and at different age groups (P < 0.001). Healthy controls had higher BMI than those with NPC (P < 0.005), but there was no difference across the age subgroups. In the NPC group, the absolute numbers of LYM, ALB, and TBNK (CD3+, CD3+CD4+, CD3+ CD8 +, CD16+CD56+, and CD19+) cell subsets were lower than those in the healthy control group (P < 0.001). A comparison of lymphocyte subpopulations in nasopharyngeal carcinomas at different stages revealed that CD3+CD8+(%) in N3 patients was higher than in N0-2. Patients who acquired metastases had higher CD19+ (%). The multifactorial combination index for the differential diagnosis of NPC, which included PNI, EBV, and immunological status, had a sensitivity of 81.59% and specificity of 96.08%.
Conclusions
The nutritional and immune statuses of NPC patients were reduced prior to treatment, and the evaluation of nutritional and immune statuses prior to treatment of patients with NPC at the time of diagnosis is of guiding significance for subsequent anti-tumor treatment, which is worth promoting and applying in the clinic.
Legal entity responsible for the study
The authors.
Funding
Sichuan Science and Technology Program (2023NSFSC1446).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
88P - Utilisation of the ESMO-MCBS in prioritising immune-checkpoint inhibitors for a WHO model list of essential medicines application
Presenter: Mario Csenar
Session: Poster Display session
Resources:
Abstract
89P - Safety and efficacy of rechallenge with immune checkpoint inhibitors in advanced solid tumor: A systematic review and meta-analysis
Presenter: Huijun Xu
Session: Poster Display session
Resources:
Abstract
90P - Meta-analysis of hypophysitis incidence in melanoma patients treated with immune checkpoint inhibitors
Presenter: Vincas Urbonas
Session: Poster Display session
Resources:
Abstract
91P - Territorial disparities in the use of hospitalization at home for immune checkpoint inhibitors infusion in France between 2021 and 2022
Presenter: Anne Claire Toffart
Session: Poster Display session
Resources:
Abstract
93P - Pseudoprogression in immunotherapy: Illusion or reality? P-PIT study
Presenter: Amelie Toulet
Session: Poster Display session
Resources:
Abstract
94P - Real-world characteristics, treatments and healthcare recourse utilization (HCRU) of patients (pts) with advanced/metastatic non-small cell lung cancer (mNSCLC) managed with first line (1L) immuno-oncology (IO) strategies in Greece: The IO-HORIZON study
Presenter: Dimitrios Ziogas
Session: Poster Display session
Resources:
Abstract
95P - Quality of life (QoL) and care pathway in patients with durable response to immune checkpoint inhibitors (ICI-DR) for advanced or metastatic non-small cell lung cancer (NSCLC) or melanoma: QUALICI study
Presenter: Nicolas Girard
Session: Poster Display session
Resources:
Abstract
96P - Comparative cardiovascular risks of PD-1 vs. PD-L1 inhibitors: A meta-analysis of incidence and severity of cardiotoxicity
Presenter: Mohammedbaqer Al-Ghuraibawi
Session: Poster Display session
Resources:
Abstract
97P - Cardiac risk stratification and serial monitoring during immune checkpoint inhibitor therapy: Prospective real-world experience
Presenter: James Knott
Session: Poster Display session
Resources:
Abstract
98P - Immuno-related cardiac toxicity: a prospective study applying multiparametric cardiac MRI
Presenter: Agnese Losurdo
Session: Poster Display session
Resources:
Abstract